QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:ZNTL

Zentalis Pharmaceuticals - ZNTL Stock Forecast, Price & News

$19.43
-0.72 (-3.57%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.06
$20.24
50-Day Range
$18.39
$25.60
52-Week Range
$17.33
$85.95
Volume
418,813 shs
Average Volume
622,319 shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.56

Zentalis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
139.6% Upside
$46.56 Price Target
Short Interest
Bearish
10.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Zentalis Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.47 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.63) to ($4.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

435th out of 1,023 stocks

Pharmaceutical Preparations Industry

191st out of 501 stocks

ZNTL stock logo

About Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Receive ZNTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZNTL Stock News Headlines

4 Analysts Have This to Say About Zentalis Pharmaceuticals
Analyst Ratings for Zentalis Pharmaceuticals
Zentalis Pharmaceuticals has a new chief medical officer
See More Headlines
Receive ZNTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZNTL Company Calendar

Last Earnings
11/10/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZNTL
Fax
N/A
Employees
177
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.56
High Stock Price Forecast
$74.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+139.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-158,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.05 per share

Miscellaneous

Free Float
45,712,000
Market Cap
$1.11 billion
Optionable
Not Optionable
Beta
1.80

Key Executives

  • Dr. Kimberly Lynn Blackwell M.D. (Age 53)
    CEO & Director
    Comp: $46.08k
  • Mr. Cameron S. Gallagher M.B.A. (Age 52)
    Co-Founder, Pres & Director
    Comp: $515.18k
  • Dr. Kevin D. Bunker Ph.D. (Age 50)
    Co-Founder & Chief Scientific Officer
    Comp: $648.84k
  • Ms. Melissa B. Epperly M.B.A.Ms. Melissa B. Epperly M.B.A. (Age 44)
    CFO & Treasurer
    Comp: $610.29k
  • Adam Levy
    Sr. VP of Investor Relations
  • Ms. Andrea Paul J.D. (Age 41)
    Gen. Counsel & Corp. Sec.
  • Dr. Peter Huang Ph.D.
    Sr. VP of Discovery Research
  • Dr. Meena Rao Ph.D.
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Carrie Brownstein M.D. (Age 52)
    Chief Medical Officer
  • Dr. Mark Lackner Ph.D. (Age 55)
    Chief Translational Officer & Head of Biomarker Strategy













ZNTL Stock - Frequently Asked Questions

Should I buy or sell Zentalis Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZNTL shares.
View ZNTL analyst ratings
or view top-rated stocks.

What is Zentalis Pharmaceuticals' stock price forecast for 2023?

9 Wall Street analysts have issued 1 year price objectives for Zentalis Pharmaceuticals' stock. Their ZNTL share price forecasts range from $27.00 to $74.00. On average, they expect the company's share price to reach $46.56 in the next twelve months. This suggests a possible upside of 139.6% from the stock's current price.
View analysts price targets for ZNTL
or view top-rated stocks among Wall Street analysts.

How have ZNTL shares performed in 2022?

Zentalis Pharmaceuticals' stock was trading at $84.06 at the beginning of the year. Since then, ZNTL stock has decreased by 76.9% and is now trading at $19.43.
View the best growth stocks for 2022 here
.

When is Zentalis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ZNTL earnings forecast
.

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($1.31) by $1.22.

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Phillips 66 (PSX).

When did Zentalis Pharmaceuticals IPO?

(ZNTL) raised $131 million in an initial public offering (IPO) on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

What is Zentalis Pharmaceuticals' stock symbol?

Zentalis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZNTL."

Who are Zentalis Pharmaceuticals' major shareholders?

Zentalis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.20%), BlackRock Inc. (5.85%), State Street Corp (4.99%), Tybourne Capital Management HK Ltd. (4.03%), Price T Rowe Associates Inc. MD (3.89%) and Eventide Asset Management LLC (3.26%). Insiders that own company stock include Alexis Pinto, Anthony Y Sun, Cam Gallagher, David Michael Johnson, Dimitris Voliotis, Global Investors Lp Viking, Kevin D Bunker, Kevin D Bunker, Kimberly Blackwell and Melissa B Epperly.
View institutional ownership trends
.

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zentalis Pharmaceuticals' stock price today?

One share of ZNTL stock can currently be purchased for approximately $19.43.

How much money does Zentalis Pharmaceuticals make?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) has a market capitalization of $1.11 billion. The company earns $-158,730,000.00 in net income (profit) each year or ($4.72) on an earnings per share basis.

How many employees does Zentalis Pharmaceuticals have?

The company employs 177 workers across the globe.

How can I contact Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals' mailing address is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. The official website for the company is www.zentalis.com. The company can be reached via phone at 212-433-3791 or via email at thoffmann@soleburytrout.com.

This page (NASDAQ:ZNTL) was last updated on 12/6/2022 by MarketBeat.com Staff